Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | UBE2M | P61081 | 1/20 | 0.50 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476586 | 0.92 | HSD17B10 (0.55) | HSD17B10MAPTTSHRHDAC1ALDH1A1 | |
| SCHEMBL2474354 | 0.90 | MAPT (0.57) | MCHR1HSD17B10MAPTUBE2MDCUN1D1 | |
| SCHEMBL2473792 | 0.90 | ALDH1A1 (0.54) | HSD17B10MAPTTSHRHDAC1ALDH1A1 | |
| SCHEMBL2477227 | 0.89 | OPRM1 (0.52) | HSD17B10MAPTTSHRHDAC1ALDH1A1 | |
| SCHEMBL2473980 | 0.89 | ALDH1A1 (0.54) | HSD17B10MAPTTSHRHDAC1ALDH1A1 | |
| SCHEMBL2476138 | 0.89 | MCHR1 (0.52) | MCHR1HSD17B10MAPTUBE2MDCUN1D1 | |
| SCHEMBL2478140 | 0.88 | HSD17B10 (0.52) | HSD17B10MAPTTSHRHDAC1ALDH1A1 | |
| SCHEMBL2534529 | 0.88 | UBE2M (0.51) | HSD17B10MAPTUBE2MDCUN1D1TSHR | |
| SCHEMBL2474808 | 0.88 | ALDH1A1 (0.54) | MCHR1HSD17B10MAPTTSHRHDAC1 | |
| SCHEMBL2475852 | 0.88 | OPRM1 (0.53) | HSD17B10MAPTTSHRHDAC1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-2107052-B1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2107052-A1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | MCHR1 2116/4885HSD17B10 2033/4885MAPT 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.